First human test for new allergy drug shows promise
NCT ID NCT03570957
Summary
This early-stage study aimed to check the safety and measure how the body processes a new allergy medication called MT-2990. It involved 75 adults with seasonal allergies to Japanese cedar pollen. Researchers gave a single dose and then monitored participants for side effects and tracked their allergy symptoms in a special pollen exposure chamber.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.